Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses (income):
Research and development	$ 415,000	$ 803,000	$ 1,321,000	$ 12,377,000
General and administrative	2,408,000	4,363,000	8,603,000	13,201,000
GNI cost-sharing reimbursement	(1,200,000)		(1,200,000)
Gain on disposal of assets, net			(4,736,000)	(57,245,000)
Total operating expenses (income)	1,623,000	5,166,000	3,988,000	(30,869,000)
Income (loss) from operations	(1,623,000)	(5,166,000)	(3,988,000)	31,663,000
Interest and other income, net	47,000	282,000	216,000	549,000
Income (loss) before income taxes	(1,576,000)	(4,884,000)	(3,772,000)	32,212,000
Income tax expenses	0	0	16,000	0
Net income (loss) and comprehensive income (loss)	$ (1,576,000)	$ (4,884,000)	$ (3,788,000)	$ 32,212,000
Net income (loss) per share attributable to common stockholders, basic	$ (0.04)	$ (0.16)	$ (0.1)	$ 1.02
Net income (loss) per share attributable to common stockholders, diluted	$ (0.04)	$ (0.16)	$ (0.1)	$ 1.02
Shares used to compute net income (loss) per share attributable to common stockholders, basic	37,976,764	31,484,542	37,845,900	31,472,666
Shares used to compute net income (loss) per share attributable to common stockholders, diluted	37,976,764	31,484,542	37,845,900	31,605,834
Cash dividends paid per common share		$ 1.43	$ 0.24	$ 1.43
Contingent Value Rights Agreement
Operating expenses (income):
Cash dividends paid per common share	$ 0.05		$ 0.17
Collaboration
Revenue:
License and collaboration revenue				$ 794,000
Cost of collaboration
Operating expenses (income):
Cost of license and collaboration				$ 798,000